Literature DB >> 35609165

Rare Case of Mixed Phenotype Acute Leukemia Presenting as a Myeloid Sarcoma Without Leukemic Involvement.

Jeffrey Means1, David Feldman1, Allison Shaw2, Khoan Vu3.   

Abstract

INTRODUCTION: Mixed phenotype acute leukemia (MPAL) is a rare type of acute leukemia with immunophenotypic features of both myeloid-derived and lymphoid-derived lineages. CASE
PRESENTATION: We present an atypical case of a 32-year-old woman presenting with an anterior mediastinal mass and pericardial/pleural involvement that was initially diagnosed as primary mediastinal diffuse large B-cell lymphoma. However, flow cytometry on pleural fluid confirmed the diagnosis of MPAL of B-cell/myeloid lineage without peripheral blood/bone marrow involvement. The patient was treated with an acute lymphoblastic leukemia-type regimen and proceeded with myeloablative allogeneic hematopoietic cell transplantation in first complete remission.
CONCLUSION: MPAL can rarely present with isolated extramedullary disease without leukemic involvement and can often be misdiagnosed as a non-Hodgkin lymphoma. Careful integration of all the clinical data, particularly flow cytometry results, can clarify the diagnosis and change the treatment plan.

Entities:  

Mesh:

Year:  2022        PMID: 35609165      PMCID: PMC9126535          DOI: 10.7812/TPP/21.070

Source DB:  PubMed          Journal:  Perm J        ISSN: 1552-5767


  20 in total

1.  Acute leukemias of ambiguous lineage: diagnostic consequences of the WHO2008 classification.

Authors:  W van den Ancker; M Terwijn; T M Westers; P A Merle; E van Beckhoven; A M Dräger; G J Ossenkoppele; A A van de Loosdrecht
Journal:  Leukemia       Date:  2010-05-20       Impact factor: 11.528

2.  How I treat mixed-phenotype acute leukemia.

Authors:  Ofir Wolach; Richard M Stone
Journal:  Blood       Date:  2015-01-20       Impact factor: 22.113

3.  Comparison of outcomes in mixed phenotype acute leukemia patients treated with chemotherapy and stem cell transplantation versus chemotherapy alone.

Authors:  Hong Tian; Yang Xu; Liming Liu; Lingzhi Yan; Zhengming Jin; Xiaowen Tang; Yue Han; Zhengzheng Fu; Huiying Qiu; Aining Sun; Depei Wu
Journal:  Leuk Res       Date:  2016-04-04       Impact factor: 3.156

4.  Acute leukemia incidence and patient survival among children and adults in the United States, 2001-2007.

Authors:  Graça M Dores; Susan S Devesa; Rochelle E Curtis; Martha S Linet; Lindsay M Morton
Journal:  Blood       Date:  2011-11-15       Impact factor: 22.113

Review 5.  Mixed-phenotype acute leukemia: historical overview and a new definition.

Authors:  O K Weinberg; D A Arber
Journal:  Leukemia       Date:  2010-09-16       Impact factor: 11.528

Review 6.  Extramedullary Manifestations of Myeloid Neoplasms.

Authors:  Carla S Wilson; L Jeffrey Medeiros
Journal:  Am J Clin Pathol       Date:  2015-08       Impact factor: 2.493

7.  Therapy for children and adults with mixed phenotype acute leukemia: a systematic review and meta-analysis.

Authors:  Maria Maruffi; Richard Sposto; Matthew J Oberley; Lynn Kysh; Etan Orgel
Journal:  Leukemia       Date:  2018-02-27       Impact factor: 11.528

8.  Prognostic implications of the immunophenotype in biphenotypic acute leukemia.

Authors:  Je-Hwan Lee; Yoo Hong Min; Chul Won Chung; Byoung Kook Kim; Hwi-Joong Yoon; Deog-Yeon Jo; Ho-Jin Shin; Soo-Mee Bang; Jong-Ho Won; Dae Young Zang; Hyeoung Joon Kim; Hyun-Sook Chi; Kyoo-Hyung Lee; June-Won Cheong; Jin Seok Kim; Sun Hee Kim; Seonyang Park; Su Yon Park; Joo Seop Chung; Jae Hoon Lee; Chan-Jeoung Park
Journal:  Leuk Lymphoma       Date:  2008-04

9.  Clinical features and outcomes of extramedullary myeloid sarcoma in the United States: analysis using a national data set.

Authors:  G Goyal; A C Bartley; M M Patnaik; M R Litzow; A Al-Kali; R S Go
Journal:  Blood Cancer J       Date:  2017-08-25       Impact factor: 11.037

10.  Clinical Characteristics And Outcome Of Biphenotypic Acute Leukemia: 10 Case Reports And Literature Review.

Authors:  Jifeng Yu; Yingmei Li; Haizhou Xing; Yue Pan; Hui Sun; Dingming Wan; Yanfang Liu; Xinsheng Xie; Chong Wang; Ling Sun; Kai Sun; Zhongxing Jiang
Journal:  Cancer Manag Res       Date:  2019-10-31       Impact factor: 3.989

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.